Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy

Background. The wide availability of monoclonal antibodies for the add-on therapy of severe asthma currently allows for the personalization of biologic treatment by selecting the most appropriate drug for each patient. However, subjects with overlapping allergic and eosinophilic phenotypes can be of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelaia, Corrado, Crimi, Claudia, Nolasco, Santi, Carpagnano, Giovanna Elisiana, Brancaccio, Raffaele, Buonamico, Enrico, Campisi, Raffaele, Gagliani, Claudia, Patella, Vincenzo, Pelaia, Girolamo, Valenti, Giuseppe, Crimi, Nunzio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698313/
https://www.ncbi.nlm.nih.gov/pubmed/34944638
http://dx.doi.org/10.3390/biomedicines9121822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698313/
https://www.ncbi.nlm.nih.gov/pubmed/34944638
http://dx.doi.org/10.3390/biomedicines9121822

Ejemplares similares